Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis

Sabrina Paganoni, Theodore Hyman, Amy Shui, Peggy Allred, Matthew Harms, Jingxia Liu, Nicholas Maragakis, David Schoenfeld, Hong Yu, Nazem Atassi, Merit Cudkowicz, Timothy M. Miller

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Introduction: The aim of this study was to determine whether a history of pre-morbid type 2 diabetes mellitus (DM2) is a prognostic factor in amyotrophic lateral sclerosis (ALS). Methods: The relationship between DM2 and survival was analyzed in a study population consisting of 1,322 participants from 6 clinical trials. Results: Survival did not differ by diabetes status (log-rank test, P=0.98), but did differ by body mass index (BMI) (log-rank test, P=0.008). In multivariate analysis, there was no significant association between diabetes and survival (P=0.18), but the risk of reaching a survival endpoint decreased by 4% for each unit increase in baseline BMI (HR 0.96, 95% CI 0.94-0.99, P=0.001). DM2 was less prevalent among ALS clinical trial participants than predicted. Conclusions: A history of pre-morbid DM2 is not an independent prognostic factor in ALS clinical trial databases. The low DM2 prevalence rate should be examined in a large, prospective study to determine whether DM2 affects ALS risk.

Original languageEnglish
Pages (from-to)339-343
Number of pages5
JournalMuscle and Nerve
Issue number3
StatePublished - Sep 1 2015


  • ALS
  • BMI
  • Diabetes
  • Prognosis
  • Survival


Dive into the research topics of 'Pre-morbid type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this